Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Hannouf, Malek B ^a   Xie, Bin ^a   Brackstone, Muriel ^a   Zaric, Gregory S ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

21 gene recurrence score assay; Breast cancer; Chemotherapy; Cost effectiveness

Indexed keywords

21 GENE RECURRENCE SCORE; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; CLINICAL PRACTICE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; EARLY CANCER; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PATIENT CODING; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; CANADA; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; LYMPH NODES; MARKOV CHAINS; MENOPAUSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE;

EID: 84866778297     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-447     Document Type: Article

References (66)

1. Canadian Cancer Society/National Cancer Institute of Canada Canadian Cancer Statistics 2011, Toronto, Canada, Canadian Cancer Society/National Cancer Institute of Canada.
2. Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M. Trends in breast cancer by race and ethnicity. CA Cancer J Clin 2003, 53:342-355. 10.3322/canjclin.53.6.342, 15224974.
3. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001, 344:1997-2008. 10.1056/NEJM200106283442607, 11430330.
4. Adjuvant systemic therapy for women with node-negative breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 1998, 3(158):S43-S51. .
5. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 1998, 52:261-288. 10.1023/A:1006141703224, 10066087.
6. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?. Breast Cancer Res Treat 1998, 52:305-319. 10.1023/A:1006197805041, 10066089.
7. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
8. Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG, Shak S. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005, 11:8623-8631. 10.1158/1078-0432.CCR-05-0735, 16361546.
9. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734. 10.1200/JCO.2005.04.7985, 16720680.
10. Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol 2008, 4:603-610. 10.2217/14796694.4.5.603, 18922117.
11. Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE, Wickerham DL, Wolmark N. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010, 28:1677-1683. 10.1200/JCO.2009.23.7610, 2849763, 20065188.
12. Hall PS, McCabe C, Brown JM, Cameron DA. Health economics in drug development: efficient research to inform healthcare funding decisions. Eur J Cancer 2010, 46:2674-2680. 10.1016/j.ejca.2010.06.122, 20655197.
13. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Breast Cancer, (version 2.2008) 2010, http://www.nccn.org/profesionals/physician_gls/f_guidelines.asp. Accessed on November 18, 2010, National Comprehensive Cancer Network.
14. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312. 10.1200/JCO.2007.14.2364, 17954709.
15. Ragaz J. The 21-gene assay: impact on breast cancer in Canada. Report Card on Cancer in Canada 2009-2010, Winter: Cancer Advocacy Coalition of Canada, Emerson D, Major P, 12.
16. Ragaz J. The 21-Gene Assay, Part 2, Canada's Uneven Response. Report Card on Cancer in Canada 2010-2011, 41-43. 13.
17. Ontario Health Technology Advisory Committee (OHTAC) Recommendation Multi-gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer 2010, http://www.health.gov.on.ca/english/providers/program/ohtac/tech/recommend/rec_gep_20101213.pdf. Accessed on May 5, 2012, Ontario Health Technology Advisory Committee (OHTAC) Recommendation.
18. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005, 11:313-324.
19. Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 2007, 109:1011-1018. 10.1002/cncr.22506, 17311307.
20. Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H, Toi M. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Res Treat 2008, 112:175-187. 10.1007/s10549-007-9842-y, 18075786.
21. Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat 2011, 127:739-749. 10.1007/s10549-010-1243-y, 21082239.
22. Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization. Value Health 2010, 13:381-387. 10.1111/j.1524-4733.2010.00724.x, 20412544.
23. Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 2010, 15:457-465. 10.1634/theoncologist.2009-0275, 3227972, 20421264.
24. Lamond NW, Skedgel C, Rayson D, Lethbridge L, Younis T. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat 2012, 133:1115-1123. 10.1007/s10549-012-1989-5, 22361999.
25. Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol 2008, 21:1255-1261. 10.1038/modpathol.2008.54, 18360352.
26. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993, 13:322-338. 10.1177/0272989X9301300409, 8246705.
27. Laupacis A. Economic evaluations in the canadian common drug review. PharmacoEconomics 2006, 24:1157-1162. 10.2165/00019053-200624110-00011, 17067199.
28. Latosinsky S, Fradette K, Lix L, Hildebrand K, Turner D. Canadian breast cancer guidelines: have they made a difference?. CMAJ 2007, 176:771-776. 10.1503/cmaj.060854, 1808531, 17353529.
29. The American Joint Committee on Cancer Staging Manual 1997, Philadelphia: Lippincott-Raven Publishers, Fleming ID, Cooper JS, Henson D, 5, The American Joint Committee on Cancer Staging Manual.
30. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
31. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989, 4:362-366. 10.1016/0888-7543(89)90343-1, 2565881.
32. Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A, Coussens L. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985, 229:976-978. 10.1126/science.2992090, 2992090.
33. Slamon DJ, Clark GM. Amplification of c-erbB-2 and aggressive human breast tumors?. Science 1988, 240:1795-1798. 10.1126/science.3289120, 3289120.
34. Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, Reimer T, Paepke S, Azim HA, Ragosch V, Kubista E, Baumgartner AK, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2012, 21:27-33. 10.1016/j.breast.2011.07.006, 21862331.
35. Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg 1999, 230:692-696. 10.1097/00000658-199911000-00012, 1420924, 10561094.
36. Albanell J, Colomer R, Ruiz-Borrego M, et al. Prospective TRANSGEICAM Study of OncotypeDX® in clinical decision making in estrogen receptor positive node negative breast cancer women [abstract]. 35th European Society for Medical Oncology (ESMO) Congress 2010, Abstract 222PD.
37. Oratz R, Paul D, Cohn AL, Sedlacek SM. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 2007, 3:182-186. 10.1200/JOP.0742001, 2793805, 20859407.
38. Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?. Am J Surg 2008, 196:527-529. 10.1016/j.amjsurg.2008.06.021, 18809056.
39. Erb C, Fox KR, Patel M, et al. Evaluation of practice patterns in the treatment of node-negative, hormone-receptor positive breast cancer patients with the use of the oncotype DX assay at the University of Pennsylvania. Presentation at the 30th Annual San Antonio Breast Cancer Symposium 2007, San Antonio, TX, Abstract 3082.
40. Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, Albain KS. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010, 28:1671-1676. 10.1200/JCO.2008.20.2119, 20065191.
41. Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol 2008, 26:925-933. 10.1200/JCO.2006.10.4190, 18281666.
42. Statistics Canada/Health Statistics Division Life Tables, Canada and the Provinces, 2000-2002 2006, Ottawa, Ontario, Canada: Minister of Industry, publication, 84-537-XIE, Statistics Canada/Health Statistics Division.
43. Gluck S. Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. Oncologist 2005, 10:780-791. 10.1634/theoncologist.10-10-780, 16314288.
44. Martin M, Segui MA, Anton A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodriguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 2010, 363:2200-2210. 10.1056/NEJMoa0910320, 21121833.
45. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials 2005, 1687-1717. Lancet, 365, .
46. Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 2005, 23:8313-8321. 10.1200/JCO.2005.08.071, 16293862.
47. Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 2003, 14:833-842. 10.1093/annonc/mdg260, 12796019.
48. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006, 98:1108-1117. 10.1093/jnci/djj305, 16912263.
49. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002, 20:4636-4642. 10.1200/JCO.2002.05.088, 2566741, 12488407.
50. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383. 10.1016/0021-9681(87)90171-8, 3558716.
51. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006, 26:391-400. 10.1177/0272989X06290497, 16855127.
52. Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 1993, 11:771-776.
53. Desch CE, Hillner BE, Smith TJ, Retchin SM. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 1993, 11:777-782.
54. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000, 18:3302-3317.
55. Fryback DG, Lawrence WF. Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments. Med Decis Making 1997, 17:276-284. 10.1177/0272989X9701700303, 9219187.
56. Kornblith AB, Herndon JE, Weiss RB, Zhang C, Zuckerman EL, Rosenberg S, Mertz M, Payne D, Jane Massie M, Holland JF, Wingate P, Norton L, et al. Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer 2003, 98:679-689. 10.1002/cncr.11531, 12910510.
57. Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. CMAJ 1993, 148:927-929. 1490721, 8448707.
58. Rocchi A, Menon D, Verma S, Miller E. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health 2008, 11:771-783. 10.1111/j.1524-4733.2007.00298.x, 18179658.
59. Muszbek N, Shah S, Carroll S, McDonald H, Dale P, Maroun J, Knox J. Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. Curr Med Res Opin 2008, 24:3559-3569. 10.1185/03007990802563706, 19032137.
60. Chabot I, Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value Health 2010, 13:837-845. 10.1111/j.1524-4733.2010.00738.x, 20561332.
61. Ioannidis JP. Is molecular profiling ready for use in clinical decision making?. Oncologist 2007, 12:301-311. 10.1634/theoncologist.12-3-301, 17405894.
62. Cree M, Tonita J, Turner D, Nugent Z, Alvi R, Barss R, King C, Winget M. Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004. Clin Colorectal Cancer 2009, 8:141-145. 10.3816/CCC.2009.n.023, 19632928.
63. Baunemann Ott CL, Ratna N, Prayag R, Nugent Z, Badiani K, Navaratnam S. Survival and treatment patterns in elderly patients with advanced non-small-cell lung cancer in Manitoba. Curr Oncol 2011, 18:e238-e242. 3185905, 21980255.
64. Cooke AL, Appell R, Suderman K, Fradette K, Latosinsky S. Radiation treatment waiting times for breast cancer patients in Manitoba, 2001 and 2005. Curr Oncol 2009, 16:58-64. 2768502, 19862362.
65. Oratz R, Chao C, Skrzypezak S, et al. Effect of a 21-gene reverse-transcriptase polymerase chain reaction assay on treatment recommendations for patients with lymph node-positive and estrogen receptor-positive breast cancer. Cancer Res 2009, 69(24): . abstract 2031, 2795111, 19996295.
66. Mink D, von Tongelen B, Villena-Heinsen C, Heiss C, Schmidt W. Breast cancer and prognostic factors. Tumour size, degree of differentiation, proliferation kinetics and expression of steroid hormone receptors. Eur J Gynaecol Oncol 1994, 15:424-436.